– NASDAQ:RGNX
stock price today
$8.4
+0.98
+13.36%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
stock price monthly change
-41.97%
month
stock price quarterly change
-41.97%
quarter
stock price yearly change
-60.73%
year
key metrics
Market Cap | 365.09M |
Enterprise value | 764.61M |
P/E | -2.86 |
EV/Sales | 6.78 |
EV/EBITDA | -2.97 |
Price/Sales | 6.80 |
Price/Book | 1.48 |
PEG ratio | N/A |
EPS | -5.88 |
Revenue | 86.72M |
EBITDA | -250.68M |
Income | -260.14M |
Revenue Q/Q | -18.37% |
Revenue Y/Y | -20.90% |
Profit margin | -248.68% |
Oper. margin | -233.2% |
Gross margin | 51.61% |
EBIT margin | -233.2% |
EBITDA margin | -289.06% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freestock price history
stock forecast
financial statements
Average Price Target
$26.33
Potential upside: 213.49%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 19.97M | -72.06M | -360.72% |
|---|---|---|---|
| Sep 2023 | 28.91M | -61.86M | -213.97% |
| Dec 2023 | 22.21M | -62.88M | -283.12% |
| Mar 2024 | 15.62M | -63.33M | -405.39% |
| Jun 2023 | 682458000 | 276.60M | 40.53% |
|---|---|---|---|
| Sep 2023 | 633786000 | 270.68M | 42.71% |
| Dec 2023 | 573970000 | 262.22M | 45.69% |
| Mar 2024 | 629215000 | 238.54M | 37.91% |
| Jun 2023 | -47.32M | 55.21M | -9.16M |
|---|---|---|---|
| Sep 2023 | -49.40M | 38.65M | -4.80M |
| Dec 2023 | -40.76M | 33.97M | -11.96M |
| Mar 2024 | -55.45M | 13.18M | 120.72M |
alternative data
| Aug 2023 | 401 |
|---|---|
| Sep 2023 | 401 |
| Oct 2023 | 401 |
| Nov 2023 | 401 |
| Dec 2023 | 401 |
| Jan 2024 | 401 |
| Feb 2024 | 401 |
| Mar 2024 | 344 |
| Apr 2024 | 344 |
| May 2024 | 344 |
| Jun 2024 | 344 |
| Jul 2024 | 344 |
other data
78.66%
-4.69%
of RGNX is owned by hedge funds
177
+10
34.54M
-988.70K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 45000 |
| Jan 2024 | 0 | 62237 |
| Feb 2024 | 0 | 15000 |
| Mar 2024 | 0 | 27878 |
| Apr 2024 | 0 | 15000 |
| May 2024 | 0 | 15000 |
| Jul 2024 | 0 | 10000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KARABELAS ARGERIS N director | Stock Options (Right to Buy) | 10,000 | $3.76 | $37,600 | ||
Option | KARABELAS ARGERIS N director | Common Stock | 10,000 | $3.76 | $37,600 | ||
Sale | KARABELAS ARGERIS N director | Common Stock | 10,000 | $11.27 | $112,690 | ||
Option | MILLS KENNETH T. director, officer.. | Common Stock | 15,000 | $3.76 | $56,400 | ||
Option | MILLS KENNETH T. director, officer.. | Stock Options (Right to Buy) | 15,000 | $3.76 | $56,400 | ||
Sale | MILLS KENNETH T. director, officer.. | Common Stock | 15,000 | $15.82 | $237,225 | ||
Option | MILLS KENNETH T. director, officer.. | Common Stock | 15,000 | $3.76 | $56,400 | ||
Sale | MILLS KENNETH T. director, officer.. | Common Stock | 15,000 | $18.19 | $272,865 | ||
Option | MILLS KENNETH T. director, officer.. | Stock Options (Right to Buy) | 15,000 | $3.76 | $56,400 | ||
Option | VASISTA VITTAL officer: Chief Fi.. | Common Stock | 20,041 | $3.76 | $75,354 |
| Patent |
|---|
Application Filling date: 25 Aug 2020 Issue date: 8 Sep 2022 |
Application METHODS OF SIZE EXCLUSION CHROMATOGRAPHY FOR THE CHARACTERIZATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS COMPOSITIONS Filling date: 10 Apr 2020 Issue date: 1 Sep 2022 |
Application Filling date: 10 Jul 2020 Issue date: 11 Aug 2022 |
Application Filling date: 12 Jan 2022 Issue date: 7 Jul 2022 |
Application Filling date: 24 Apr 2020 Issue date: 23 Jun 2022 |
Application Filling date: 2 Apr 2020 Issue date: 16 Jun 2022 |
Application Filling date: 17 Apr 2020 Issue date: 12 May 2022 |
Application Filling date: 2 Apr 2020 Issue date: 12 May 2022 |
Application Filling date: 22 Oct 2021 Issue date: 31 Mar 2022 |
Application Filling date: 13 Nov 2019 Issue date: 23 Dec 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Kenneth T. Mills (1975) Pres, Chief Executive Officer & Director | $997,830 |
| Mr. Vittal K. Vasista (1968) Senior Vice President & Chief Financial Officer | $650,850 |
| Dr. Olivier Danos Ph.D. (1958) Senior Vice President & Chief Scientific Officer | $623,860 |
Mr. Curran M. Simpson M.S. (1962) Senior Vice President and Chief Operations & Technology Officer | $618,540 |
| Mr. Patrick J. Christmas II (1971) Senior Vice President & Chief Legal Officer | $613,140 |
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome
Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
Ocular Is Now Thoroughly Derisked
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Regenxbio: Biotech To Watch With 2 Possible Accelerated Approval Pathways
Orchard Therapeutics: A Reassessment
Regenxbio: RGX-314 Continues Advancing With Solid Financials
-
What's the price of stock today?
One share of stock can currently be purchased for approximately $8.4.
-
When is 's next earnings date?
Unfortunately, 's (RGNX) next earnings date is currently unknown.
-
Does pay dividends?
No, does not pay dividends.
-
How much money does make?
has a market capitalization of 365.09M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 19.94% to 90.24M US dollars.
-
What is 's stock symbol?
null is traded on the NASDAQ under the ticker symbol "RGNX".
-
What is 's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ?
Shares of can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 's key executives?
's management team includes the following people:
- Mr. Kenneth T. Mills Pres, Chief Executive Officer & Director(age: 50, pay: $997,830)
- Mr. Vittal K. Vasista Senior Vice President & Chief Financial Officer(age: 57, pay: $650,850)
- Dr. Olivier Danos Ph.D. Senior Vice President & Chief Scientific Officer(age: 67, pay: $623,860)
- Mr. Curran M. Simpson M.S. Senior Vice President and Chief Operations & Technology Officer(age: 63, pay: $618,540)
- Mr. Patrick J. Christmas II Senior Vice President & Chief Legal Officer(age: 54, pay: $613,140)
-
How many employees does have?
As Jul 2024, employs 344 workers.
-
When went public?
null is publicly traded company for more then 9 years since IPO on 17 Sep 2015.
-
What is 's official website?
The official website for is regenxbio.com.
-
Where are 's headquarters?
is headquartered at 9804 Medical Center Drive, Rockville, MD.
-
How can i contact ?
's mailing address is 9804 Medical Center Drive, Rockville, MD and company can be reached via phone at +240 5528181.
-
What is stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for in the last 12 months, the avarage price target is $26.33. The average price target represents a 213.49% change from the last price of $8.4.
company profile:
Exchange:
NASDAQ
Full time employees:
344
Industry:
Biotechnology
Sector:
Healthcare
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
9804 Medical Center Drive
Rockville, MD 20850
Rockville, MD 20850
CIK: 0001590877
ISIN: US75901B1070
CUSIP: 75901B107
